• 1. An assay for the enzyme N-acetyl-β-d-glucosaminidase (NAGase) based on electrochemical detection using screen-printed carbon electrodes (SPCEs)
  R. M. Pemberton,J. P. Hart,T. T. Mottram Analyst, 2001,126, 1866-1871
• 2. An Assessment of the Laminar Hypersonic Double-Cone Experiments in the LENS-XX Tunnel
  JaideepRay,PatrickBlonigan,EricT.Phipps,KathrynMaupin
• 3. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 4. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 5. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrazoles Indazoles

Recent Advances in the Study of 5-Bromo-4-fluoro-3-iodo-1H-indazole (CAS: 1082041-88-0)

5-Bromo-4-fluoro-3-iodo-1H-indazole (CAS: 1082041-88-0) is a halogenated indazole derivative that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug discovery. This compound serves as a versatile building block for the synthesis of various biologically active molecules, particularly in the development of kinase inhibitors and other targeted therapies. Recent studies have explored its utility in the design of novel anticancer agents, highlighting its importance in the field of chemical biology and pharmaceutical research.

One of the key areas of research involving 5-Bromo-4-fluoro-3-iodo-1H-indazole is its role in the synthesis of small-molecule inhibitors targeting protein kinases. Kinases are critical regulators of cellular signaling pathways, and their dysregulation is often implicated in cancer and other diseases. Researchers have utilized this compound as a scaffold to develop potent and selective inhibitors for kinases such as BRAF, EGFR, and JAK2. A recent study published in the Journal of Medicinal Chemistry demonstrated the successful incorporation of this indazole derivative into a series of compounds with promising activity against BRAF-mutant melanoma cells.

In addition to its applications in kinase inhibitor development, 5-Bromo-4-fluoro-3-iodo-1H-indazole has also been investigated for its potential in radiopharmaceuticals. The presence of multiple halogen atoms, including iodine, makes it a suitable candidate for radiolabeling studies. A 2023 study in the European Journal of Nuclear Medicine and Molecular Imaging reported the synthesis of a radiolabeled analog of this compound for use in positron emission tomography (PET) imaging. The study highlighted its favorable pharmacokinetic properties and potential for visualizing tumor tissues in preclinical models.

The synthetic routes to 5-Bromo-4-fluoro-3-iodo-1H-indazole have also been a focus of recent research. Optimized protocols for its preparation have been developed to improve yield and purity, which are critical for its use in drug discovery. A recent publication in Organic Process Research & Development described a scalable and efficient method for the synthesis of this compound, emphasizing the importance of controlling reaction conditions to minimize byproducts and ensure reproducibility.

Despite its promising applications, challenges remain in the utilization of 5-Bromo-4-fluoro-3-iodo-1H-indazole. Issues such as solubility, stability, and off-target effects of derived compounds need to be addressed in future studies. However, ongoing research continues to explore its potential, with several patents filed in the past year covering novel derivatives and their therapeutic applications. The compound's versatility and the growing body of research supporting its use suggest that it will remain a valuable tool in chemical biology and drug development for years to come.

In conclusion, 5-Bromo-4-fluoro-3-iodo-1H-indazole (CAS: 1082041-88-0) represents a promising scaffold in medicinal chemistry, with applications ranging from kinase inhibitors to radiopharmaceuticals. Recent studies have expanded our understanding of its potential, and ongoing research is likely to uncover new opportunities for its use in drug discovery. As the field advances, this compound is expected to play an increasingly important role in the development of targeted therapies for cancer and other diseases.

• 2432848-78-5(6-Bromo-7-fluoro-3-iodo-1H-indazole)
• 1352398-23-2(5-bromo-7-fluoro-3-iodo-1H-indazole)
• 518990-32-4(4-Fluoro-3-iodo-1H-indazole)
• 1000342-12-0(7-bromo-4-fluoro-3-iodo-1h-indazole)
• 1286734-77-7(6-bromo-5-fluoro-3-iodo-1h-indazole)
• 1286734-96-0(6-bromo-5-fluoro-3-iodo-1-methyl-1h-indazole)
• 887567-87-5(4-Bromo-6-fluoro-3-iodo-1H-indazole)
• 887568-00-5(6-Bromo-4-fluoro-3-iodo-1H-indazole)
• 633335-82-7(5-Bromo-6-fluoro-3-iodo-1H-indazole)
• 887567-79-5(4,6-Difluoro-3-iodo-1H-indazole)